Skip to main content
. 2017 Jun 15;2(2):88–92. doi: 10.1016/j.ncrna.2017.06.002

Table 1.

Dysregulated small non-coding RNAs in the four most common cancers [1].

Type of cancer Biomarker sncRNAs Elevated levels Down-regulated
Lung cancer miR-29c,
miR-93,
miR-429,
miR-19a,
miR-17-5p,
miR-210,
miR-21,
miR-486,
miR-145,
miR-155,
miR-146b,
miR-221,
miR-let-7a,
miR-27a,
miR-106a,
miR-29c,
miR-20a-5p,
miR-25-3p,
miR-191-5p,
miR-223-3p,
miR-296-5p,
miR-320-3p,
miR-let-7f-5p,
miR-24-3p,
miR-126-3p,
miR-145-5p,
miR-152-3p,
miR-199a-5p,
miR-197,
miR-182 [2].		 miR-21,
miR-17,
miR-155,
miR-150,
miR-3940-5p,
miR-183,
miR-30e-5p,
miR-125a-5p,
miR-let-7e,
miR-19a [2];
piR-651 [3].		 miR-31,
miR-10a, 16 [2];
piR-L-163 [3].
Breast cancer let-7a,
let-7b,
let-7c,
miR-1308,
miR-21,
miR-494,
miR-923 [5];
miR-15a,
miR-18a,
miR-107,
miR-425,
miR-133a,
miR-133b,
miR-139-5p,
miR-143,
miR-145,
miR-365,
miR-155,
miR-1,
miR-92a,
miR-148b,
miR-376c,
miR-409-3p,
miR-801,
miR-16,
miR-21,
miR-451,
miR-145 [6].		 miR-21,
miR-155,
miR-10b,
miR-373/520c,
miR-27a,
miR-221/222 [4];
miR-183 [5];
miR-10b,
miR-155,
miR-373,
miR-520c [6];
miR-30b-5p,
miR-182-5p,
miR-374b-5p,
miR-942b-5p [7];
piR-4987,
piR-20365,
piR-20485,
piR-20582,
piR-36743,
piR-36026,
piR-31106 [3, 8].		 MiR-206,
miR-17-5p,
miR-125a,b,
miR-200c,
let-7,
miR-34a,
miR-31,
miR-335,
miR-27b,
miR-126,
miR-101,
miR-145,
miR-146a/b,
miR-205 [4];
miR-125b,
miR-205,
miR-17-92,
miR-206,
miR-200,
miR-146b,
miR-126,
miR-335,
miR-31 [6];
piR-34736,
piR-36249,
piR-35407,
piR-36318,
piR-34377 [3, 8].
Colorectal cancer miR-92a [9]. Let-7,
miR-17-5p,
miR-20a,
miR-29a,
miR-21,
miR-31,
miR-92a,
miR-181b,
miR-203 [9];
let-7g,
miR-15b,
miR-192,
miR-215,
miR-21,
miR-200 [10].		 miR-106a,
miR-126,
miR-143,
miR-145 [9];
miR-145,
miR-15a,
miR-181b [10].
Prostate cancer miR-222-3p,
miR-24-3p,
miR-30c-5p,
miR-125b-5p,
let-7a-5p,
miR-151-5p [13].		 miR-30c,
miR-122,
miR-125a,
miR-181a,
miR-181c,
miR-146b-5p,
miR-184,
miR-193a,
miR-193b,
miR-214,
let-7f,
miR-1,
miR-17,
miR-98,
miR-122,
miR-125b,
miR-125a-5p,
miR-144,
miR-142-5p,
miR-146b-5p,
miR-181a,
miR-210,
miR-32,
miR-98,
miR-138,
miR-142p,
miR-144,
miR-181c,
miR-183,
miR-184,
miR-205,
miR-206,
miR-215,
miR-272,
miR-301 [11];
miR-125b,
miR-21,
miR-17-92,
miR-25,
miR-205,
miR-24,
miR-629,
miR-660,
miR-20a,
miR-107,
miR-143,
miR-141,
miR-221,
miR-375 [12];
miR-30a/b/c-5p,
miR-125b-5p [13].		 miR-15-16,
miR-145,
miR-107,
miR-205,
miR-29b,
miR-331-3p [12];
miR-31-5p,
miR-141-3p,
miR-146a-5p,
miR-24-3p,
miR-222-3p [13].

References:

[1.] J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr, accessed on 16/01/2015.

[2.] A. Markou, M. Zavridou, E.S. Lianidou, MicroRNA signatures as clinical biomarkers in lung cancer, Curr. Biomarker Findings, 5 (2015) 35–45.

[3.] K.W. Ng, C. Anderson, E.A. Marshall, B.C. Minatel, K.S.S. Enfield, H.L. Saprunoff, W.L. Lam, V.D. Martinez, Piwi-interacting RNAs in cancer: emerging functions and clinical utility, Mol. Canc., 15 (2016) 5–18.

[4.] S.W. Fu, L. Chen, Y.-G. Man, miRNA biomarkers in breast cancer detection and management, J. Canc., 2 (2011) 116–122.

[5.] A.L.F. Marino, A.F. Evangelista, R.A.C. Vieira, T. Macedo, L.M. Kerr, L.F. Abrahao-Machado, A. Longatto-Filho, H.C.S. Siveira, M.M.C. Marques, MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. BMC Canc., 14 (2014) 739–751.

[6.] E. van Schooneveld, H. Wildiers, I. Vergote, P.B. Vermeulen, L.Y. Dirix, S.J. van Laere, Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management, Breast Canc. Res., 17 (2015) 21–40.

[7.] K. Zhang, Y.-W. Wang, Y.-Y. Wang, Y. Song, J. Zhu, P.-C. Si, R. Ma, Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling, Gene 619 (2017) 10–20.

[8.] P. Krishnan, S. Ghosh, K. Graham, J.R. Mackey, O. Kovalchuk, S. Damaraju, Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer, Oncotarget, 7(25) (2016) 37944–37956.

[9.] K. Schee, O. Fodstad, K. Flatmark, Micro-RNAs as biomarkers in colorectal cancer, Am. J. Pathol., 177 (2010) 1592–1599.

[10.] J. Yang, D. Ma, A. Fesler, H. Zhai, A. Leamniramit, W. Li, S. Wu, J. Ju, Expression analysis of microRNA as prognostic biomarkers in colorectal cancer, Oncotarget Adv. Publications, (2016) 1–10.

[11.] B.A. Walter, V.A. Valera, P.A. Pinto, M.J. Merino, Comprehensive microRNA profiling of prostate cancer, J. Canc. 4(5) (2013) 350–357.

[12.] B.L. Jackson, A. Grabowska, H.L. Ratan, MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers, BMC Canc., 14 (2014) 930–939.

[13.] J. Fredsoe, A.K.I. Rasmussen, A.R. Thomsen, P. Mouritzen, S. Hoyer, M. Borre, T.F. Orntoft, K.D. Sorensen, Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine, Eur. Urol. Focus Prostate Canc., 297 (2017) 1–9.